Compare Ginkgo Bioworks Holdings Inc (DNA) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Lamb Weston Holdings Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $8.98 (market cap $590.53M), while Lamb Weston Holdings Inc trades at $45.61 (market cap $6.42B). The key difference: Lamb Weston Holdings Inc is far larger — about 10.9× Ginkgo Bioworks Holdings Inc's market cap, and Lamb Weston Holdings Inc pays a 3.27% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | LW | |
|---|---|---|
Market Cap | $590.53M | $6.42B |
Sector | Health | Consumer Staples |
52-Week High | $16.14 | $66.57 |
52-Week Low | $5.48 | $38.48 |
Enterprise Value | $627.78M | $10.38B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Lamb Weston (LW) trades at $46.98, up 1.14% with a bullish technical signal and consistent earnings beats. The company shows strong operational cash flow of $868.3M in 2025 and maintains positive revenue growth, though net income margin declined to 4.61%. Recent news highlights the 'Focus to Win' strategy showing early traction with North America volume gains and cost savings.
Outlook remains cautiously optimistic with analyst consensus price target of $49.33 offering 5% upside. Key risks include ongoing securities litigation and margin pressure from competitive dynamics. Institutional sentiment leans positive with activist involvement signaling potential value creation opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
